Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LJPC-401 in hereditary hemochromatosis with iron overload
2017-003598-33Phase 2Completed
- Sponsor
- La Jolla Pharmaceutical Company
- Start
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in hereditary hemochromatosis (HH) comparing LJPC-401 weekly with Placebo weekly (2 arms). Primary endpoint: Change in transferrin saturation (TSAT). Started Dec 2017; status: completed.
02
Drugs
hepcidin
03
Conditions
hereditary hemochromatosis (HH)
Beyond the preview
Go deeper on 2017-003598-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003598-33.